RNAi is invaluable as an R&D and drug discovery tool, and holds great commercial value in identifying new disease targets. Hence, companies like Sirna Therapeutics involved in RNAi-based therapeutics are acquired by big pharma companies like Merck & Co. for a premium of more than twice their market cap. However the hope for RNAi has been to develop novel therapeutics that has yet to be realized.